Navigate Fool.com
Will CLDX beat
the market?
Community Rating: 3 Stars: Appealing

14.24 -0.45 (-3.06%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $14.62
Previous Close $14.69
Daily Range $14.11 - $14.93
52-Week Range $11.34 - $38.84
Market Cap $1.3B
P/E Ratio -13.96
Dividend (Yield) $0.00 (0.0%)
Volume 2,536,066
Average Daily Volume 2,798,872
Current FY EPS -$1.09

How do you think CLDX
will perform against the market?

Top CLDX Bull/Bear Pitches


KattyKayK (< 20)
Submitted October 6, 2010

Celldex Therapeutics, Inc. has strong science underlying it's drug candidates. The therapeutic use of a vaccine to 'teach' the immune system to control or remove the cancer cells is a unique niche th … More

0 Replies Reply Report this Post

chtrplyr (< 20)
Submitted June 6, 2008

It will be bought out at $5 when it runs out of money which is has none of now along with huge losses.

0 Replies Reply Report this Post

News & Commentary Rss Feed

5 Stocks Forging the Future of Breast Cancer Care

Pharmacotherapies for breast cancer are undergoing an innovation boom. Which biotechs offer the most compelling investment opportunities in this space?

3 Biggest Biotech Crashes in March

Here's why Celldex (CLDX), Acceleron (XLRN), and Newlink (NLNK) all tumbled in March.

Are These 3 Biotechs Bad News Buys?

With biotech stocks taking a step back in March, let's review three of the biggest busts of the sector over the past month

Jefferies Biotech Stocks to Buy With Breakthrough Drug Innovations

3 Biotechs Falling Like a Knife: Arrowhead, Celldex, Receptos

Although biotech in general has been having a rough go, these three stocks are falling like a knife.

Mid-Afternoon Market Update: Markets Recover Slightly As Healthcare Stocks Continue to Show Weakness

Mid-Day Market Update: NASDAQ Tumbles 1.65%; Nu Skin Shares Surge After AIC China Review Update

Cancer Vaccines: Doomed to Fail?

Another cancer vaccine comes up short in a pivotal study, casting doubt on the approach as a whole.

Is Celldex's Loss Alexion's Gain?

Celldex's potential Soliris-killer bites the dust, leaving Alexion large and in charge in its corner of the complement-mediated rare kidney disease world.

Oppenheimer Top Stocks to Buy as Bull Market Turns Five Years Old

See More CLDX News...





Celldex Therapeutics, Inc. (CLDX) Description

A biopharmaceutical company engaged in the discovery, development and commercialization of products that harness the human immune response to prevent and treat disease. Website: http://www.celldex.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks